The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Translational Psychiatry Année : 2021

The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study

1 Institute of Psychiatry, Psychology & Neuroscience, King's College London
2 SLAM - South London and Maudsley NHS Mental Health Foundation Trust
3 University of Heidelberg, Medical Faculty
4 MUMC - Maastricht University Medical Centre
5 MRC Centre for Neuropsychiatric Genetics and Genomics
6 Cardiff University
7 Università degli studi di Palermo - University of Palermo
8 VBPI - Villa Betania Psychological Institute [Reggio Calabria, Italy]
9 UCL - University College of London [London]
10 UMCG - University Medical Center Groningen [Groningen]
11 CAM - University of Cambridge [UK]
12 CPFT - Cambridgeshire & Peterborough NHS Foundation Trust [Cambridge]
13 UNIBO - Alma Mater Studiorum Università di Bologna = University of Bologna
14 UNIVR - Università degli studi di Verona = University of Verona
15 U955 Inserm - UPEC - IMRB - "Neuropsychiatrie translationnelle" [Créteil]
16 UCM - Universidad Complutense de Madrid = Complutense University of Madrid [Madrid]
17 IiSGM - Instituto de Investigación Sanitaria Gregorio Marañón / Institute of Health Research Gregorio Marañón [Madrid, Spain]
18 CIBER-SAM - Centro de Investigación Biomédica en Red Salud Mental [Madrid]
19 Hospital General Universitario "Gregorio Marañón" [Madrid]
20 Clinic Barcelona Hospital Universitari
21 University of Barcelona
22 IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer
23 University of Oviedo
24 ISPA - Institute for Health Research of the Principality of Asturias [Oviedo,Spain]
25 USP - Universidade de São Paulo = University of São Paulo
26 IP - Institut Pascal
27 UCA - Université Clermont Auvergne
28 INP Clermont Auvergne - Institut national polytechnique Clermont Auvergne
29 HVDL - Hospital Virgen de La Luz [Cuenca, Spain]
30 UCV - Universidad Catolica de Valencia San Vicente Mártir = Saint Vincent the Martyr Catholic University of Valencia
31 CHUS - Complejo Hospitalario Universitario de Santiago de Compostela [Saint-Jacques-de-Compostelle, Espagne]
32 EPSMB - Établissement Public de Santé Maison Blanche [Paris]
33 MSSM - Icahn School of Medicine at Mount Sinai [New York]
34 UvA - University of Amsterdam [Amsterdam] = Universiteit van Amsterdam
35 University of Bath [Bath]
36 HKU - The University of Hong Kong
37 Li Kashing Faculty of Medicine [Hong Kong]
38 Leeds Institute of Health Sciences
39 University of Leeds
40 UMCU - University Medical Center [Utrecht]
Bart P F Rutten
James B Kirkbride

Résumé

Diagnostic categories do not completely reflect the heterogeneous expression of psychosis. Using data from the EU-GEI study, we evaluated the impact of schizophrenia polygenic risk score (SZ-PRS) and patterns of cannabis use on the transdiagnostic expression of psychosis. We analysed first-episode psychosis patients (FEP) and controls, generating transdiagnostic dimensions of psychotic symptoms and experiences using item response bi-factor modelling. Linear regression was used to test the associations between these dimensions and SZ-PRS, as well as the combined effect of SZ-PRS and cannabis use on the dimensions of positive psychotic symptoms and experiences. We found associations between SZ-PRS and (1) both negative (B = 0.18; 95%CI 0.03-0.33) and positive (B = 0.19; 95%CI 0.03-0.35) symptom dimensions in 617 FEP patients, regardless of their categorical diagnosis; and (2) all the psychotic experience dimensions in 979 controls. We did not observe associations between SZ-PRS and the general and affective dimensions in FEP. Daily and current cannabis use were associated with the positive dimensions in FEP (B = 0.31; 95%CI 0.11-0.52) and in controls (B = 0.26; 95%CI 0.06-0.46), over and above SZ-PRS. We provide evidence that genetic liability to schizophrenia and cannabis use map onto transdiagnostic symptom dimensions, supporting the validity and utility of the dimensional representation of psychosis. In our sample, genetic liability to schizophrenia correlated with more severe psychosis presentation, and cannabis use conferred risk to positive symptomatology beyond the genetic risk. Our findings support the hypothesis that psychotic experiences in the general population have similar genetic substrates as clinical disorders.
Fichier principal
Vignette du fichier
s41398-021-01526-0.pdf (1.27 Mo) Télécharger le fichier
Origine Publication financée par une institution
Licence

Dates et versions

inserm-04197703 , version 1 (06-09-2023)

Licence

Identifiants

Citer

Diego Quattrone, Ulrich Reininghaus, Alex L Richards, Giada Tripoli, Laura Ferraro, et al.. The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study. Translational Psychiatry, 2021, 11 (1), pp.423. ⟨10.1038/s41398-021-01526-0⟩. ⟨inserm-04197703⟩
1 Consultations
6 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More